Cargando…

Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program

INTRODUCTION: Dupilumab is a monoclonal antibody targeting IL-4Rα recently licensed for severe asthma (SA). A Named Patients Program (NPP) was created in Italy before its commercial availability for SA patients with no other available therapeutic options. We aimed to assess the real-world effectiven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campisi, Raffaele, Crimi, Claudia, Nolasco, Santi, Beghè, Bianca, Antonicelli, Leonardo, Guarnieri, Gabriella, Scichilone, Nicola, Porto, Morena, Macchia, Luigi, Scioscia, Giulia, Foschino Barbaro, Maria Pia, Papi, Alberto, Crimi, Nunzio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167193/ https://www.ncbi.nlm.nih.gov/pubmed/34079295 http://dx.doi.org/10.2147/JAA.S312123

Ejemplares similares

Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use
por: Nolasco, Santi, et al.
Publicado: (2020)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
por: Crimi, Claudia, et al.
Publicado: (2020)

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study
por: Campisi, Raffaele, et al.
Publicado: (2023)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
por: Pelaia, Corrado, et al.
Publicado: (2023)

Practical considerations for spirometry during the COVID-19 outbreak: Literature review and insights
por: Crimi, Claudia, et al.
Publicado: (2021)

Personalized Medicine in Asthma: Current Approach and Future Perspectives
por: Nolasco, Santi, et al.
Publicado: (2023)

Adherence to omalizumab: A multicenter "real-world" study
por: Campisi, Raffaele, et al.
Publicado: (2020)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

Switching Biological Therapies in Severe Asthma
por: Scioscia, Giulia, et al.
Publicado: (2023)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study
por: Nolasco, Santi, et al.
Publicado: (2023)

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2020)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Type 2-High Severe Asthma with and without Bronchiectasis: A Prospective Observational Multicentre Study
por: Crimi, Claudia, et al.
Publicado: (2021)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
por: Pelaia, Corrado, et al.
Publicado: (2021)

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
por: Pelaia, Corrado, et al.
Publicado: (2021)

Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis
por: Canonica, Giorgio Walter, et al.
Publicado: (2021)

Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study
por: Crimi, Claudia, et al.
Publicado: (2022)

Resumption of respiratory outpatient services in the COVID-19 era: Experience from Southern Italy
por: Crimi, Claudia, et al.
Publicado: (2020)

Utility of ultrasound assessment of diaphragmatic function before and after pulmonary rehabilitation in COPD patients
por: Crimi, Claudia, et al.
Publicado: (2018)

Patients and doctors group meetings: an innovative way to explore severe asthma backstage
por: Caminati, Marco, et al.
Publicado: (2022)

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis
por: Di Bona, Danilo, et al.
Publicado: (2021)

Reliability and usefulness of a rapid IgM‐IgG antibody test for the diagnosis of SARS-CoV-2 infection: A preliminary report.
por: Spicuzza, Lucia, et al.
Publicado: (2020)

High Level of Blood Eosinophils and Localization of Bronchiectasis in Patients with Severe Asthma: A Pilot Study
por: Quaranta, Vitaliano Nicola, et al.
Publicado: (2023)

Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study
por: Quaranta, Vitaliano Nicola, et al.
Publicado: (2022)

Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2022)

Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics
por: Scichilone, N., et al.
Publicado: (2016)

Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2021)

Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial
por: Papi, Alberto, et al.
Publicado: (2012)

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype
por: Lacedonia, Donato, et al.
Publicado: (2017)

Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
por: Pelaia, Corrado, et al.
Publicado: (2022)

Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
por: Carpagnano, Giovanna E, et al.
Publicado: (2019)

Tocilizumab and liver injury in patients with COVID-19
por: Serviddio, Gaetano, et al.
Publicado: (2020)

Antibiotic Treatment of Severe Exacerbations of Chronic Obstructive Pulmonary Disease with Procalcitonin: A Randomized Noninferiority Trial
por: Verduri, Alessia, et al.
Publicado: (2015)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
por: Scioscia, Giulia, et al.
Publicado: (2020)

Choosing wisely in Allergology: a Slow Medicine approach to the discipline promoted by the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC)
por: Heffler, Enrico, et al.
Publicado: (2015)

Rate of Decline of FEV(1) as a Biomarker of Survival?
por: Papi, Alberto, et al.
Publicado: (2021)

MicroRNA expression profile during different conditions of hypoxia
por: Lacedonia, Donato, et al.
Publicado: (2018)

Is the Power Spectrum of Electromyography Signal a Feasible Tool to Estimate Muscle Fiber Composition in Patients with COPD?
por: Casabona, Antonino, et al.
Publicado: (2021)

Real life experience of molnupiravir as a treatment of SARS-CoV-2 infection in vaccinated and unvaccinated patients: a letter on its effectiveness at preventing hospitalization
por: Scioscia, Giulia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_imfag48oou1lpm677svd28p403